PK/PD, METABOLIC, AND PRECLINICAL STUDIES - SRI INTERNATIONAL

PK/PD、代谢和临床前研究 - SRI INTERNATIONAL

• 批准号: 10833878
• 负责人: DEBRA BURNIN
• 金额: $ 208.5万
• 依托单位: SRI INTERNATIONAL
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-04-13 至 2025-04-12
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10833878
• 关键词: ADME Study; Androgens; Animal Model; Animals; Area; Biological Testing; Blood; Clinical; Clinical Research; Clinical Trials; Clinical Trials Network; Contraceptive Agents; Contraceptive Devices; Contraceptive methods; Contractor; Development; Drug Evaluation; Drug Formulations; Drug Kinetics; Endocrine; Enrollment; Evaluation; Excretory function; Formulation; Goals; Good Manufacturing Process; Hormones; In Vitro; Injectable; International; Investigational New Drug Application; Metabolic; Methods; Microsomes; Mission; Modeling; National Institute of Child Health and Human Development; Oral; Ovulation; Pharmaceutical Preparations; Pharmacodynamics; Pharmacologic Substance; Phase; Plasma; Play; Process; Prodrugs; Production; Progestins; Program Development; Proteins; Protocols documentation; Report (document); Research; Research Personnel; Research Support; Role; Route; Safety; System; Testing; Tissues; Toxic effect; Toxicology; Woman; androgenic; candidate identification; chemical synthesis; clinical lot; design; drug candidate; drug development; efficacy evaluation; estrogenic; in vitro Assay; in vivo; lot production; manufacture; men; metabolic abnormality assessment; new chemical entity; novel therapeutics; pharmacokinetics and pharmacodynamics; population health; pre-clinical; preclinical study; product development; programs; recruit; research and development; research clinical testing; screening; sperm cell; sperm function; stability testing

At NICHD, within the Division of Intramural Population Health Research (DiPHR), the Contraceptive Development Program (CDP) supports research and development of potential contraceptive agents that can disrupt normal ovulation, sperm production or sperm function for the purpose of developing safe, effective, and affordable contraceptives for women or men. The Biological Testing Facility (BTF) is designed to allow rapid evaluation of new chemical entities (NCE), drug formulations, delivery systems, and devices for contraceptive and endocrine activity. The BTF provides overall project management and the capabilities to support all phases of preclinical activities pursuant to development of new contraceptive methods: these include, but are not limited to in vitro assays and in vivo studies, plasma and microsomal stability studies, absorption, distribution, metabolism, excretion and toxicity (ADMET), pharmacokinetic (PK) and pharmacodynamic (PD) profiling, animal activities and studies, manufacture of active pharmaceutical ingredients (APIs), process and product development, formulation, clinical lot production, preclinical enabling studies and associated tasks leading to the filing of investigational new drug (IND) applications. Compounds formulated by the BTF are prepared under current Good Manufacturing Practices (cGMP) to allow clinical evaluation in the CDP Contraceptive Clinical Trials Network (CCTN). The CCTN investigators have develop protocols to evaluate the drug candidates identified as high priority by the Program. The BTF has been working with the CORs for the Chemical Synthesis Facility and the CCTN and with the investigators in the CCTN to develop and test the appropriate formulations for clinical batches of the candidate compounds. The next clinical study for each candidate drug is dependent on timely receipt of clinical batches to begin the process of recruitment and enrollment. Drugs that are currently in ongoing clinical trials require stability testing of the clinical formulations. The Biological Testing Facility plays a critical role in the drug development mission of the CDP.

在NICHD，在校内人口健康研究司（DiPHR）内，避孕开发计划（CDP）支持研究和开发可能破坏正常排卵，精子生产或精子功能的潜在避孕药，以开发安全，有效和负担得起的女性或男性避孕药。生物试验设施（BTF）旨在快速评价新的化学实体（NCE）、药物制剂、给药系统以及避孕和内分泌活性装置。 BTF提供全面的项目管理和能力，以支持根据新避孕方法开发的临床前活动的所有阶段：这些包括但不限于体外测定和体内研究，血浆和微粒体稳定性研究，吸收、分布、代谢、排泄和毒性（ADMET），药代动力学（PK）和药效学（PD）分析，动物活动和研究，活性药物成分（API）的生产、工艺和产品开发、配方、临床批量生产、临床前使能研究以及导致提交研究性新药（IND）申请的相关任务。由BTF配制的化合物根据现行药品生产质量管理规范（cGMP）制备，以便在CDP避孕临床试验网络（CCTN）中进行临床评价。CCTN研究人员已经制定了方案，以评估该计划确定为高优先级的候选药物。BTF一直在与化学合成机构和CCTN的COR以及CCTN的研究人员合作，开发和测试候选化合物临床批次的适当配方。 每种候选药物的下一项临床研究取决于是否及时收到临床批次，以开始招募和入组过程。目前正在进行临床试验的药物需要进行临床制剂的稳定性试验。生物试验机构在CDP的药物开发使命中发挥着关键作用。